You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

Claims for Patent: 11,884,634

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,884,634

Title:	Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
Abstract:	The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Inventor(s):	Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
Assignee:	Pfizer Corp SRL
Application Number:	US18/057,633
Patent Claims:	1. A pharmaceutical composition comprising a solid form of a hydrobromide salt of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide, wherein the solid form is characterized by a differential scanning calorimetry profile comprising a phase transition at a temperature selected from about 39, 65, 69, 80, 87, 122, 139, 143, 152, 157, 160, 213, 222, 223, 230, and 274° C. 2. The pharmaceutical composition of claim 1 wherein the differential scanning calorimetry profile comprises a phase transition at about 274° C. 3. The pharmaceutical composition of claim 1 wherein the differential scanning calorimetry profile comprises a phase transition at about 39 and 152° C. 4. The pharmaceutical composition of claim 1 wherein the differential scanning calorimetry profile comprises a phase transition at about 65° C. 5. The pharmaceutical composition of claim 1 wherein the differential scanning calorimetry profile comprises a phase transition at about 80° C. 6. The pharmaceutical composition of claim 1 wherein the differential scanning calorimetry profile comprises a phase transition at about 157° C.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.